These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28700501)

  • 21. Metformin and lung cancer risk in patients with type 2 diabetes mellitus.
    Tseng CH
    Oncotarget; 2017 Jun; 8(25):41132-41142. PubMed ID: 28456789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis.
    Kalsekar ID; Madhavan SS; Amonkar MM; Douglas SM; Makela E; Elswick BL; Scott V
    Clin Ther; 2006 Feb; 28(2):306-18. PubMed ID: 16678652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes.
    Lin SY; Tu HP; Lu PL; Chen TC; Wang WH; Chong IW; Chen YH
    Respirology; 2018 Nov; 23(11):1063-1073. PubMed ID: 29943489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
    Kuan YC; Huang KW; Lin CL; Hu CJ; Kao CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):77-83. PubMed ID: 28583443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
    Raju A; Shetty S; Cai B; D'Souza AO
    J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan.
    Chang CH; Sakaguchi M; Dolin P
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1196-1203. PubMed ID: 27221971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of type 2 diabetes on postoperative outcome after hip fracture: nationwide population-based study in Taiwan.
    Lee TC; Lee YL; Chen JC; Chen CH; Ho PS
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32086279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin reduces risk of varicose veins in patients with type 2 diabetes.
    Tseng CH
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3206. PubMed ID: 31322821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study.
    Oh TK; Song IA
    Acta Diabetol; 2021 Jun; 58(6):771-778. PubMed ID: 33582839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin and Risk of Hypertension in Taiwanese Patients With Type 2 Diabetes Mellitus.
    Tseng CH
    J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29954747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis.
    Tseng CH
    J Am Heart Assoc; 2019 Nov; 8(21):e011640. PubMed ID: 31630591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.
    Chang CH; Chang YC; Lin JW; Chen ST; Chuang LM; Lai MS
    J Clin Endocrinol Metab; 2015 Mar; 100(3):1121-9. PubMed ID: 25555040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC
    Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.